Incannex Executes 1-for-30 Reverse Stock Split to Avoid Nasdaq Delisting
Event summary
- Incannex Healthcare approved a 1-for-30 reverse stock split, reducing outstanding shares from ~358M to ~12M.
- The split takes effect February 26, 2026, with trading on a split-adjusted basis beginning February 27, 2026.
- The move aims to meet Nasdaq's $1 minimum bid price requirement for continued listing.
- Shareholders holding physical certificates must exchange them through Computershare Trust Company.
- No fractional shares will be issued; fractional positions will be rounded up to whole shares.
The big picture
Incannex's reverse stock split is a defensive maneuver to avoid Nasdaq delisting, a common strategy for biotech firms facing liquidity challenges. The move reflects broader industry trends where clinical-stage pharmaceutical companies balance financial engineering with the need to attract investment for drug development. The split's success hinges on whether it stabilizes the stock price while maintaining investor confidence in the company's pipeline.
What we're watching
- Compliance Sustainability
- Whether the reverse stock split will successfully maintain Nasdaq listing compliance.
- Market Reaction
- How investors respond to the reduced share count and adjusted trading price.
- Operational Focus
- The pace at which Incannex advances its clinical-stage drug candidates post-split.
Related topics